NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has drawn attention to its broad-spectrum antiviral candidate NV-387 in light of the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain, emphasizing its proposed mechanism targeting viral cell attachment pathways common across filoviruses.
According to the press release, NV-387 is positioned as a potential pandemic preparedness tool for Ebola and related viral threats. The company highlighted that the candidate targets pathways that are shared among filoviruses, which could make it effective against multiple strains, including the current outbreak strain. This announcement comes as health authorities work to contain the spread of the Bundibugyo Ebola virus, a less common strain that has caused sporadic outbreaks in the region.
NanoViricides is a clinical-stage company that develops special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral drug that the company plans to develop for the treatment of respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox infections and measles. The company also has other advanced drug candidates, including NV-HHV-1 for the treatment of shingles.
The company’s nanoviricide technology is based on intellectual property and proprietary know-how licensed from TheraCour Pharma, Inc. The company has obtained broad, exclusive, sub-licensable field licenses to drugs developed in several licensed fields from TheraCour. The business model is based on licensing technology for specific application verticals of specific viruses, established at its foundation in 2005.
NanoViricides is also developing drugs against a number of viral diseases, including oral and genital herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus, among others. The company holds a worldwide exclusive perpetual license to the TheraCour nanomedicine technology for several drugs with specific targeting mechanisms for the treatment of human viral diseases, including HIV/AIDS, hepatitis B, hepatitis C, rabies, herpes simplex virus, varicella-zoster virus, influenza, dengue viruses, Japanese encephalitis virus, West Nile virus, Ebola/Marburg viruses, and certain coronaviruses.
The company noted that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts, there can be no assurance at this time that any of the company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development, or that successful results in the lab will lead to successful clinical trials or a successful pharmaceutical product.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/mm3Z5.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NanoViricides Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak.